An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the efficacy of different doses and regimens of dupilumab in participants with
moderate to severe uncontrolled asthma.
Secondary Objective:
To evaluate different doses and regimens of dupilumab in participants with moderate to severe
uncontrolled asthma, with regard to:
- Safety and tolerability
- Dupilumab systemic exposure and anti-drug antibodies